Fraud & Abuse

By Kate Greenwood
In Fraud & Abuse
Sep 10th, 2014
0 Comments
This week, Seton Hall Law’s Kathleen Boozang published a blog post at Jotwell reviewing Joseph Yockey’s article Choosing Governance in the FCPA Reform Debate, which was published in the Journal of Corporation Law. Dean Boozang writes: In the end, Yockey suggests a climate that is not unlike that of healthcare enforcement more generally: ‘Some firms li...
By Charles Sullivan
In Employment Law
Mar 7th, 2014
0 Comments
The recent Supreme Court decision in Lawson v. FMR LLC,  which dramatically expanded the reach of the Sarbanes Oxley Act, is interesting in a number of respects – not least because it involved what my colleague Professor Timothy Glynn describes as “employeeless employers.” The decision has obvious implications for the publicly traded sector in the […]...
By Tara Adams Ragone
In Fraud & Abuse
Oct 17th, 2012
0 Comments
As this blog has chronicled (see here and here), New Jersey has begun implementing the 2008 legislation that authorized creation of a Prescription Drug Monitoring Program (“PMP” or “PDMP”).  Although New Jersey’s PMP database has been collecting data for more than a year, the State has not yet issued implementing regulations to flesh out t...
By Zack Buck
In Fraud & Abuse
Aug 14th, 2012
0 Comments
Over the last few weeks, the fight against healthcare fraud has prominently been in the headlines. First, late last month the Obama administration announced a joint effort between the federal government and major health insurance companies to fight fraud.  According to the New York Times, under the partnership – called the National Fraud Prevention Partnership [&hellip...
By Zack Buck
In Fraud & Abuse
Apr 15th, 2012
2 Comments
News of the $1.2 billion verdict against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals Inc. for their roles in marketing Risperdal during the middle of last decade sent reverberations through the industry earlier this week.  The award resolved Arkansas’ claims that the companies fraudulently marketed the “second generation” antipsychotic, misleading ...